| Issue |
BIO Web Conf.
Volume 121, 2024
Global Summit on Life Sciences and Bio-Innovation: From Agriculture to Biomedicine (GLSBIA 2024)
|
|
|---|---|---|
| Article Number | 03004 | |
| Number of page(s) | 5 | |
| Section | Cutting-edge Biomedicine and Pharmacological Discoveries | |
| DOI | https://doi.org/10.1051/bioconf/202412103004 | |
| Published online | 22 July 2024 | |
Efficiency of ferrotherapy when using different groups of iron drugs in patients with Helicobacter pylori
Bukhara State Medical Institute, Bukhara, Uzbekistan
* Corresponding author: dr-rano@mail.ru
To date, a number of scientific studies are being conducted in the world devoted to the study of various variants of the manifestation of helicobacteriosis. Special attention should be paid to studies on the pathogenesis of iron drugs (ID) in helicobacteriosis and the role of eradication therapy in improving the effectiveness of iron therapy. Despite the fact that there are results of numerous studies confirming the role of HP in the development of ID, there are still unresolved issues related to determining the exact indications for specific therapy aimed at eradicating this infection in cases where patients with clinical and laboratory signs of ID do not have obvious symptoms damage to the gastric mucosa.
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.